Skip to main content
Premium Trial:

Request an Annual Quote

Three RNAi-Related Patent Applications Published by the USPTO: Jan 12, 2006

Premium

Title: Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for Their Identification

Number: 20060003915

Filed: April 16, 2003 PCT Filed: April 16, 2003

Lead Inventor: Karina Drumm, University of Wurzburg

"Provided are methods for the treatment of disorders of the central nervous system and the eye," the patent application's abstract states. "In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the CNS and/or the eye, wherein the composition is designed to be administered outside the blood-CNS and the blood-retina barriers. Furthermore, methods are provided for identifying and obtaining nucleic acid molecules encoding polypeptides involved in CNS disorders or of the eye, methods for diagnosing said disorders as well as transgenic animal deficient in the expression of target genes identified in accordance with the described method," it adds. "In addition, methods of identifying and isolating drugs that are particularly useful for the treatment of disorders related to the CNS and/or the eye are disclosed."


Title: Bioinformatically Detectable Group of Novel Regulatory Genes and Uses Thereof

Number: 20060003322

Filed: Dec. 6, 2002

Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent application's abstract states, "relates to a first group of novel genes, here identified as 'genomic address messenger' or 'GAM' genes, and a second group of novel operon-like genes, here identified as 'genomic record' or 'GR' genes. GAM genes selectively inhibit translation of known target genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 20,600 GAM genes, and 6,635 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof," the abstract states.


Title: Method for Preventing or Treating Obesity by Modulating the Activities of the Pentose Phosphate Pathway

Number: 20060002922

Filed: June 30, 2005

Inventor: Zhengping Xu, Minkon Biotechnology

According to the patent application's abstract, the invention is a "method for preventing or treating overweight or obesity … comprising administering to a patient in need thereof an antagonist that inhibits gene expression or activity of an enzyme that is involved or related to the pentose phosphate pathway. Preferably, the enzyme is a transketolase, and the antagonist is an antibody, an antisense molecule, an siRNA molecule, a molecule for forming a triplex nucleic acid molecule with the enzyme-encoding polynucleotide. Also disclosed are pharmaceutical compositions comprising the same, and method for screening a substance that inhibits gene expression of a PPP enzyme or its function."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.